@article{TLCR29535,
author = {Satomi Tanaka and Junji Uchino},
title = {Erlotinib as standard adjuvant therapy for resectable EGFR mutation-positive non-small cell lung cancer},
journal = {Translational Lung Cancer Research},
volume = {8},
number = {Suppl 4},
year = {2019},
keywords = {},
abstract = {This Chinese randomized, open-label, phase 2 trial compared erlotinib with the standard-of-care vinorelbine plus cisplatin therapy as adjuvant treatment for patients with stage IIIA EGFR mutation-positive non-small cell lung cancer (NSCLC) who were able to undergo complete resection.},
issn = {2226-4477}, url = {https://tlcr.amegroups.org/article/view/29535}
}